Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Screening Test Developer New Horizon Health Goes Public in Hong Kong

NEW YORK — Chinese diagnostics firm New Horizon Health has gone public on the Hong Kong Stock Exchange, venture capital firm Qiming Venture Partners said on Thursday.

New Horizon, one of Qiming's portfolio companies, focuses on tests for early cancer screening tests and offers two fecal immunochemical tests approved in China: ColoClear for individuals at high-risk for colorectal cancer and Pupu Tube for general colorectal cancer screening.

The company is also developing a stool-based gastric cancer screening test called UU Tube and a urine-based cervical cancer screen called CerviClear, according to Qiming.

Qiming said that New Horizon's shares went public at HK$26.66 (US$3.44).

In late 2019, New Horizon partnered with Prenetics to offer ColoClear in Hong Kong and certain other Asian markets.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.